From Rare To Real: Pharma Urged To Act As China Preps New Rare Conditions List
Executive Summary
Chinese regulatory agency working around the clock in preparation to release another official list of rare diseases, and a push to launch more innovative orphan drugs is underway. But this time pharma firms need to be more proactive, noted an NMPA official.